|Bid||0.00 x 1800|
|Ask||0.00 x 3200|
|Day's Range||23.52 - 26.24|
|52 Week Range||23.08 - 50.44|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||85.44|
|Earnings Date||Aug 19, 2019 - Aug 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $984 million over the last one-month into ETFs that hold MYGN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Author Michael Crichton warned of the evils of gene patents in his 2006 novel “Next” and, more directly, in a 2007 New York Times commentary piece. Crichton’s concern about giving exclusive legal rights to the use of information about human bodies was a matter of principle: “You can’t patent snow, eagles or gravity, and you shouldn’t be able to patent genes, either. If one company develops a genetic test for a disease, for example, a patent on the gene involved might prevent scientists at a different institution from seeking possible gene therapies for the disease.
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
SALT LAKE CITY, June 05, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone,.
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
SALT LAKE CITY, June 03, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two.
“Our long-standing collaboration with Myriad Genetics Inc. has enabled us to deliver the positive POLO study in pancreatic cancer patients, demonstrating our shared ambition to target precision medicines to the right patients across different cancers,” said Ruth March, Ph.D., senior vice president and head of Precision Medicine, Oncology R&D, AstraZeneca.
Mark Capone has been the CEO of Myriad Genetics, Inc. (NASDAQ:MYGN) since 2015. First, this article will compare CEO...
SALT LAKE CITY, May 14, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis. Findings from the study were published in the journal Clinical Cancer Research.
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Salt Lake City-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share. The results topped Wall Street expectations. ...
Total Third-Quarter Revenues of $216.6 Million, Up 18 PercentThird-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 -- Myriad.